Health
Roivant's Immune Drug Success in Eye Disease Trials
Roivant reports positive results from trials of an immune drug for non-infectious uveitis, potentially opening new markets for the company. This could have significant implications for patients and the pharmaceutical industry.
Coverage timeline — 1 article
STAT News
An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.
2026-10-21 12:05 UTC